Dr Mark Andrew Rouff, MD | |
2460 S Parkview Loop Ste 3, Yuma, AZ 85364-5357 | |
(928) 336-7846 | |
(928) 336-1776 |
Full Name | Dr Mark Andrew Rouff |
---|---|
Gender | Male |
Speciality | Physical Medicine And Rehabilitation |
Experience | 10 Years |
Location | 2460 S Parkview Loop Ste 3, Yuma, Arizona |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609255512 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0000X | Pain Medicine - Pain Medicine | 67161 (Arizona) | Primary |
208100000X | Physical Medicine & Rehabilitation | A169330 (California) | Secondary |
Facility Name | Location | Facility Type |
---|---|---|
Yuma Regional Medical Center | Yuma, AZ | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Yuma Regional Medical Center | 2062314826 | 288 |
News Archive
Researchers at Boston University School of Medicine have discovered that blocking a specific protein, may be a promising strategy to prevent the spread of castration-resistant prostate cancer.
Patients researching health conditions on the internet should use reputable and frequently updated websites and not see online research as a replacement for consulting healthcare professionals, according to a paper in the May issue of the Journal of Clinical Nursing.
A study from Massachusetts General Hospital researchers finds that electronic consultations in allergy and immunology can simplify the process of providing the most appropriate care, often reducing the need for in-person specialist visits.
CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.
› Verified 8 days ago
Entity Name | Yuma Regional Medical Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1194706655 PECOS PAC ID: 2062314826 Enrollment ID: O20040122000526 |
News Archive
Researchers at Boston University School of Medicine have discovered that blocking a specific protein, may be a promising strategy to prevent the spread of castration-resistant prostate cancer.
Patients researching health conditions on the internet should use reputable and frequently updated websites and not see online research as a replacement for consulting healthcare professionals, according to a paper in the May issue of the Journal of Clinical Nursing.
A study from Massachusetts General Hospital researchers finds that electronic consultations in allergy and immunology can simplify the process of providing the most appropriate care, often reducing the need for in-person specialist visits.
CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Mark Andrew Rouff, MD 2400 S Avenue A, Yuma, AZ 85364-7170 Ph: (928) 344-2000 | Dr Mark Andrew Rouff, MD 2460 S Parkview Loop Ste 3, Yuma, AZ 85364-5357 Ph: (928) 336-7846 |
News Archive
Researchers at Boston University School of Medicine have discovered that blocking a specific protein, may be a promising strategy to prevent the spread of castration-resistant prostate cancer.
Patients researching health conditions on the internet should use reputable and frequently updated websites and not see online research as a replacement for consulting healthcare professionals, according to a paper in the May issue of the Journal of Clinical Nursing.
A study from Massachusetts General Hospital researchers finds that electronic consultations in allergy and immunology can simplify the process of providing the most appropriate care, often reducing the need for in-person specialist visits.
CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.
› Verified 8 days ago